The present invention provides methods of identifying compounds that non-specifically
inhibit biological reactions. The present invention further includes kits that
facilitate this identification. In addition, complications of compounds for use
in high throughput drug screening that have been evaluated by the disclosed methodology
are also part of the present invention. Further, the invention provides methods
for identifying a false positive compound previously identified as positive in
a screening assay by measuring the activity of at least one biological activity
in the presence and absence of a small molecule compound capable of inhibiting
aggregate formation, e.g., digitonin.
